Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601929 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| SCHEMBL4824941 | 0.85 | SRD5A2 (0.82) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| Piperonylic Acid SCHEMBL31119409 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| Piperonylic Acid SCHEMBL3946119 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| Piperonylic Acid SCHEMBL142318 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| 3,4-Methylendioxy Acetophenone SCHEMBL29405437 | 0.82 | KDM4E (0.71) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| SCHEMBL27780735 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| SCHEMBL57650 | 0.82 | TSHR (0.79) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| SCHEMBL5416122 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 | |
| SCHEMBL144609 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPK1HPGDSRD5A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5756505-A | N-acylpiperazine derivative, antibacterial drug and anti-ulcer drug | SHISEIDO CO., LTD. (JP) | 1998-05-26 | — | — | US | claimed |
| EP-1773779-B1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV LAVAL (CA) | 2013-12-04 | — | — | EP | disclosed |
| US-8557804-B2 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2013-10-15 | — | — | US | disclosed |
| US-8551983-B2 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2013-10-08 | — | — | US | disclosed |
| US-20120022049-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2012-01-26 | — | — | US | disclosed |
| US-8039459-B2 | especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids | UNIVERSITE LAVAL (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20080221085-A1 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases | UNIVERSITE LAVAL (CA) | 2008-09-11 | — | — | US | disclosed |
| EP-1773779-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-RE39088-E1 | Amide compounds and use of the same | JAPAN TOBACCO, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| WO-2006005195-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITé LAVAL (CA) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005082459-A2 | METHOD OF DECREASING BLOOD CELLS | JAPAN TOBACCO INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | JAPAN TOBACCO INC. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | TNF, IL1B, TNNI3 | ALDH1A1 358/4885MAPK1 3349/4885HPGD 185/4885 |
| US-20080221085-A1 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases | CHRNA1, CHRNG, CHRM1 | ALDH1A1 1483/4885MAPK1 2135/4885HPGD 501/4885 |
| US-20120022049-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CHRNA1, CHRNG, CHRM1 | ALDH1A1 1483/4885MAPK1 2135/4885HPGD 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.